Gonadotropin-releasing hormone: an update review of the antagonists versus agonists (Q34636636)

3 August 2017

Gonadotropin-releasing hormone: an update review of the antagonists versus agonists (English)

1 reference

3 August 2017

2

Laurence Klotz

1 reference

3 August 2017

Hein Van Poppel

1

1 reference

3 August 2017

14 March 2012

1 reference

International Journal of Urology

3 August 2017

1 reference

3 August 2017

19

1 reference

3 August 2017

7

1 reference

3 August 2017

594-601

1 reference

Testosterone surge: rationale for gonadotropin-releasing hormone blockers?

3 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

Castration-resistant prostate cancer: from new pathophysiology to new treatment targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

Therapeutic options in androgen-independent prostate cancer: building on docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

Pathways of chemotherapy resistance in castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

The gonadotropin-releasing hormone (GnRH) agonist-induced initial rise of bioactive LH and testosterone can be blunted in a dose-dependent manner by GnRH antagonist in the non-human primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

Will GnRH antagonists improve prostate cancer treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02997.X

10.1111/J.1442-2042.2012.02997.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

22416801